TITLE:
Lapatinib In Chemotherapy-Naive Or Metastatic Breast Cancer

CONDITION:
Neoplasms, Breast

INTERVENTION:
Lapatinib

SUMMARY:

      This phase II study will evaluate and compare the efficacy and tolerability of two dose
      schedules (1500 mg QD and 500 mg BID) of oral Lapatinib as treatment for patients with
      advanced or metastatic breast cancer.
    

DETAILED DESCRIPTION:
NONE

ELIGIBILITY:
Gender: Female
Age: 18 Years to N/A
Criteria:

        Inclusion criteria:

          -  Histologically confirmed invasive breast cancer with incurable stage IIIB, IIIC with
             T4 lesion or stage IV disease at primary diagnosis or at relapse after curative
             intent surgery.

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.

          -  Documented amplification of ErbB2 by Fluorescence in situ hybridization (FISH)

          -  Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST)

          -  Adequate renal, hepatic and cardiac function

        Exclusion criteria:

          -  Prior chemotherapy, immunotherapy, biologic therapy or anti-ErbB1/ErbB2 therapy other
             than adjuvant therapy. [Prior neo-adjuvant or adjuvant therapy (including
             trastuzumab) will be allowed provided it was stopped at least 12 months before study
             entry.

          -  Patients with active brain metastases

          -  Patients with bilateral breast cancer, bone metastases as the only disease site or
             metastases to more than 30% of the hepatic parenchyma.
      
